Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31197237 | 0.87 | GRIK1 (0.43) | KEAP1GRIK1GRIA2EPHX2SCD | |
| SCHEMBL31565679 | 0.85 | PARP1 (0.42) | KEAP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29629559 | 0.83 | PDE5A (0.44) | EPHX2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24468016 | 0.83 | PDE5A (0.44) | EPHX2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4272731 | 0.80 | KEAP1 (0.41) | KEAP1GRIK1GRIA2EPHX2SCD | |
| SCHEMBL4272734 | 0.80 | KEAP1 (0.41) | KEAP1GRIK1GRIA2EPHX2SCD | |
| SCHEMBL929640 | 0.80 | GRIK1 (0.62) | GRIK1GRIA2 | |
| SCHEMBL20561976 | 0.79 | EPHX2 (0.58) | GRIK1GRIA2EPHX2 | |
| SCHEMBL29956766 | 0.78 | GRIK1 (0.42) | GRIK1GRIA2EPHX2PDE4APDE4B | |
| SCHEMBL23611727 | 0.76 | KEAP1 (0.50) | KEAP1PKMPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169645-A1 | COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-06-02 | — | — | US | disclosed |
| US-20220169645-A1 | COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169645-A1 | COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | BTK, LYN, LCK | KEAP1 1962/4885GRIK1 776/4885GRIA2 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.